Sanofi and Denali Therapeutics focus on treatments for neurological conditions. Credit: Benedict Campbell/Wellcome Images/Penn State.

Sanofi has entered a deal valued at more than $1bn with US-based Denali Therapeutics to advance potential drug candidates for the treatment of neurological and systemic inflammatory diseases.

DNL747 and DNL758 are two of the several molecules to be developed by the partners.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug candidates are designed to target the receptor-interacting serine/threonine-protein kinase 1 (RIPK1) in the TNF receptor pathway associated with inflammation and cell death.

DNL747 will be evaluated in multiple sclerosis (MS), Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), and DNL758 to treat systemic inflammatory diseases such as rheumatoid arthritis.

At present, DNL747 is undergoing Phase I clinical trials. Phase Ib trials are being planned for patients with Alzheimer’s or ALS.

Denali will conduct the Phase II Alzheimer’s studies, while Sanofi will be responsible for the Phase II trials in MS and ALS, as well as future Phase III trials for all neurological indications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DNL758 is set to enter clinical trials next year; Sanofi will lead the studies for all types of systemic inflammatory diseases.

“This collaboration with Denali is yet another example of Sanofi’s commitment to accelerate the development of transformative and best-in-class treatments for patients.”

Sanofi Rare and Neurologic Diseases Research global head Rita Balice-Gordon said: “This collaboration with Denali is yet another example of Sanofi’s commitment to accelerate the development of transformative and best-in-class treatments for patients living with serious illnesses.

“We look forward to working with Denali on the RIPK1 programme as we explore the potential of this mechanism in neurologic and inflammatory diseases.”

As part of the deal, Sanofi will pay $125m upfront to Denali Therapeutics, along with future development and commercial milestone payments worth more than $1bn.

The commercial profits and losses relating to DNL747 in the US and China will be equally shared by the partners. Denali will receive a royalty on DNL747 for other territories and for DNL758 globally.